Do you taper glucocorticoids less aggressively when symptoms improve but serologies remain active in a patient with non-renal SLE?

I would worry more about the decree of immune-mediated activity, but would still move forward with aggressive steroid taper. I would monitor for increase in disease activity, ie complements and inflammatory markers closely.